FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
FreeStyle Libre 2 system is cleared to be used by children 4 years and older with Libre 2 sensor and 2 years and older with Libre 2 Plus sensor.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
Coverage and out-of-pocket costs may vary based on your individual insurance plan. Please contact your insurance provider directly to confirm your specific benefits and eligibility.
* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 and 2 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† Libre Assist is a feature within Libre app that uses generative artificial intelligence to provide information on how foods could impact your glucose levels. Generative artificial intelligence may not always be accurate, and it should not be used to make treatment decisions.
‡ The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
§ Predicted glucose impact is based on user-provided food data and may differ from actual impact, which depends on sensor readings and factors like activity, stress, medication, and alcohol.
|| Personalized food suggestions are based on food preference information inputted by the user.
¶ Study was performed with the US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 and 2 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
# Based on pharmacy claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus Dexcom CGM systems. Does not include fee-for-service Medicare or fee-for-service Medicaid. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
** Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
†† The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
‡‡ The user’s device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
References: 1. Huang, Eileen, Mohamed Nada, and Eugene Wright, Jr. "73-LB: Ambulatory Glucose Profile Informs Better Treatment Decisions for Type 2 Basal-Insulin Patients." Diabetes 71, Supplement 1 (2022): 73–LB. https://doi.org/10.2337/db22-73-LB. 2. Haak, Thomas, et al. “Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial.” Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 3. Fokkert, Marion, et al. "Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 4. FreeStyle Libre 3 User's Manual. 5. FreeStyle Libre 2 User's Manual. 6. Evans, Mark, Zoë Welsh, Sara Ells, and Alexander Seibold. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (2020): 83–95. https://doi.org/10.1007/s13300-019-00720-0. 7. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical Guidance for Using the FreeStyle Libre Flash Continuous Glucose Monitoring in Primary Care." Postgraduate Medicine 132, no. 4 (2020): 305–313. https://doi.org/10.1080/00325481.2020.1744393. 8. Data on file. Abbott Diabetes Care, Inc. 9. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People With Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294–1301. https://doi.org/10.1111/pedi.12735.
ADC-42700 v14.0